A report that had earlier been delayed by the head of the U.S. Centers for Disease Control and Prevention - and which assessed the effectiveness of COVID-19 vaccines during the recent winter season - has been prevented from being published in the agency's flagship scientific journal, according to media accounts.
Within the report, the vaccines were described as reducing emergency department visits and hospitalizations among healthy adults by approximately half over the past winter, based on information released in the reporting. The details of these findings could not be independently verified.
The Department of Health and Human Services did not reply to a request for comment about the publication decision or the assessment of vaccine effectiveness.
Oversight of federal vaccine policy by Health Secretary Robert F. Kennedy Jr. has drawn criticism from public-health experts, who have pointed to his repeated public questioning of vaccine safety and efficacy. That record of skepticism has been a focal point in discussions of his role setting federal vaccine guidance.
Under Kennedy's leadership, a panel of vaccine advisers in September withdrew a broad recommendation for COVID-19 vaccination and instead recommended that COVID shots be offered through a shared decision-making approach between a patient and a healthcare provider. That advisory change narrowed the official posture on universal recommendation and shifted emphasis to individualized discussion with clinicians.
The decision to block publication of the internal effectiveness analysis comes against that backdrop of contested federal vaccine policymaking, and it has left public and professional observers with limited official documentation available in the agency's peer-facing journal. Because the underlying report has not been published in the journal, its methods, data sources, and detailed analyses are not available for public or scientific scrutiny in that venue.
Given the absence of a published paper in the agency's scientific outlet and the lack of an official response from HHS, stakeholders outside the agency remain reliant on the summaries and accounts that have circulated in reporting. The situation highlights ongoing tensions between internal agency analyses, leadership decisions about publication, and the public visibility of vaccine effectiveness evidence.